AVC 202
Alternative Names: AVC-202Latest Information Update: 26 Apr 2023
At a glance
- Originator AvenCell Europe
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 05 Apr 2023 AVC 202 is available for licensing as of 05 Apr 2023. https://avencell.com/about/ (AvenCell Europe website, April 2023)
- 05 Apr 2023 AvenCell Europe files for patent protection for its technologies and products worldwide prior to April 2023(AvenCell Europe website, April 2023)
- 05 Apr 2023 Preclinical trials in Multiple myeloma in Germany (Parenteral) prior to April 2023 (AvenCell Europe pipeline, April 2023)